What is Biocept?
Biocept, Inc. is a company dedicated to the development and commercialization of molecular diagnostic assays. These assays provide physicians with critical, actionable information for the treatment and monitoring of cancer patients. The company's offerings include a comprehensive portfolio of blood-based liquid biopsy assays, as well as the specialized CNSide cerebrospinal fluid assay designed to detect cancer metastasis to the central nervous system. Biocept's proprietary Target Selector technology is central to its capabilities, enabling the capture and quantitative analysis of cerebrospinal fluid tumor cells for tumor-associated molecular markers. This technology, initially developed for blood applications, is now being leveraged for nationwide COVID-19 RT-PCR testing, contributing to public health efforts.
How much funding has Biocept raised?
Biocept has raised a total of $96.8M across 12 funding rounds:
Series C
$3.6M
Series D
$2.3M
Debt
$1.2M
Stock Offering
$19M
Share Placement
$9.3M
Stock Offering
$13.3M
Stock Offering
$10M
Multiple Rounds
$26.1M
Series C (2010): $3.6M, investors not publicly disclosed
Series D (2010): $2.3M, investors not publicly disclosed
Debt (2011): $1.2M, investors not publicly disclosed
Stock Issuance/Offering (2014): $19M, investors not publicly disclosed
Share Placement (2017): $9.3M led by Chardan Capital and ROTH Capital Partners
Stock Issuance/Offering (2018): $13.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $10M, investors not publicly disclosed
Share Placement (2020): $9.2M, investors not publicly disclosed
Share Placement (2020): $6.6M, investors not publicly disclosed
Share Placement (2020): $10.3M, investors not publicly disclosed
Key Investors in Biocept
Needham Capital Partners
Needham Capital Partners is an investment banking and asset management firm specializing in growth companies. With a focus on public and private financings, mergers, and acquisitions, they bring significant experience in capital markets to their portfolio companies.
Chardan Capital
Chardan Capital is an investment firm that has participated in Biocept's funding rounds. Their involvement suggests a strategic interest in the company's growth and development within the biotechnology and diagnostics sector.
ROTH Capital Partners
ROTH Capital Partners is a full-service investment banking firm that provides a range of services including capital raising and advisory. Their participation in Biocept's financing indicates support for the company's strategic objectives and expansion plans.
What's next for Biocept?
The substantial enterprise-level funding indicates Biocept is likely in a growth phase, potentially scaling its operations, expanding its assay portfolio, and increasing market penetration. The strategic nature of recent investments suggests a focus on solidifying its position in cancer diagnostics and potentially exploring new applications for its molecular diagnostic platform, such as its COVID-19 testing services. Future developments may involve further clinical validation, regulatory approvals for new assays, and strategic partnerships to enhance commercial reach.
See full Biocept company page
